Medicare & Medicaid
The senators framed the widespread availability of free tests - along with vaccination - as a means of eventually ending the pandemic.
Uncertainty over when the waiver will end may create barriers to entry for new participants, the groups say.
The company's full-year revenue grew more than $30 billion, or 11.8%, to $287.6 billion year-over-year.
The policy is set to begin in March, at which point new access restrictions will be placed on all drugs other than the company's IMiD offerings.
This applies in the 24 states where the vaccine mandate was reinstated by last week's Supreme Court's decision.
Clover saw membership growth in a number of service area counties across Georgia, New Jersey, Pennsylvania and South Carolina.
Arguments center on Aduhelm's price, its questionable clinical benefit and why the agency is going against FDA approval of the drug.
Currently, Aduhelm, made by Biogen, is the only monoclonal antibody approved by the FDA for the treatment of Alzheimer's disease.
Premiums covered the $56,000 yearly cost of the Alzheimer's drug Aduhelm, but that price has been slashed by 50%.
CEO says aggressive pricing from marketplace rivals has played a role in the new projections, shifting the focus to business-wide profitability.